VTVT - VTv Therapeutics +14% on positive TTP399 data in type 1 diabetes

VTv Therapeutics (VTVT) jumps 14% premarket after announcing data from the completed Phase 2 Simplici-T1 study that support the clinical potential of TTP399 as an oral adjunctive therapy in type 1 diabetes (T1D).The data suggests that TTP399 does not increase the risk of diabetic ketoacidosis ((DKA)), a serious and life-threatening complication and TTP399’s positive impact on ketone levels is a point of important differentiation.The treatment resulted in significant improvements in HbA1c, with reduction in bolus insulin dose, without increasing the risk of hypoglycemia or DKA. Vtv expects to initiate first pivotal study of TTP399 by the end of 2020. The data was presented at the 56th Annual Meeting of the European Association for the Study of Diabetes, held virtually September 21-25, 2020.

For further details see:

VTv Therapeutics +14% on positive TTP399 data in type 1 diabetes